GlassScriptPhysician profile
Erika Hess
NPI 1124531850
$1,329.16
in general payments reported to CMS, 2019-2025
16 companies · $258 in 2025
The $258 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $240 · 2022: $126 · 2023: $197 · 2024: $508 · 2025: $258.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $963.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $963.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $231.42 | 2021-2025 | Rybelsus, Ozempic |
| Lilly USA, LLC | $192.17 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $190.11 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $160.64 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $129.42 | 2021-2023 | Jardiance, Synjardy |
| Abbott Laboratories | $107.55 | 2022-2025 | Freestyle Libre 3 |
| Shield Therapeutics INC | $88.67 | 2023-2025 | Accrufer |
| Amgen INC. | $70.76 | 2024-2025 | Repatha, Otezla, Repatha |
| Astellas Pharma US INC | $29.41 | 2024-2025 | Veozah |
| Abbvie INC. | $29.12 | 2021 | |
| Agios Pharmaceuticals, INC. | $21.90 | 2024 | Pyrukynd |
| Pfizer INC. | $20.16 | 2024 | |
| Sumitomo Pharma America, INC. | $15.73 | 2024 | Gemtesa |
| Takeda Pharmaceuticals U.S.A., INC. | $14.79 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.77 | 2025 | Xifaxan |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $13.54 | 2023 | Segluromet, Steglujan, Steglatro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erika Hess listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.